1. Home
  2. GLO vs BWAY Comparison

GLO vs BWAY Comparison

Compare GLO & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clough Global Opportunities Fund

GLO

Clough Global Opportunities Fund

HOLD

Current Price

$5.66

Market Cap

243.8M

Sector

Finance

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$16.97

Market Cap

337.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLO
BWAY
Founded
2006
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
243.8M
337.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
GLO
BWAY
Price
$5.66
$16.97
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$23.50
AVG Volume (30 Days)
170.5K
59.2K
Earning Date
01-01-0001
11-11-2025
Dividend Yield
11.38%
N/A
EPS Growth
N/A
213.09
EPS
N/A
0.13
Revenue
N/A
$49,094,000.00
Revenue This Year
N/A
$330.76
Revenue Next Year
N/A
$22.24
P/E Ratio
N/A
$54.90
Revenue Growth
N/A
27.08
52 Week Low
$4.08
$7.84
52 Week High
$5.18
$18.18

Technical Indicators

Market Signals
Indicator
GLO
BWAY
Relative Strength Index (RSI) 46.13 54.82
Support Level $5.60 $16.75
Resistance Level $5.70 $18.18
Average True Range (ATR) 0.06 0.74
MACD -0.00 0.10
Stochastic Oscillator 40.48 69.37

Price Performance

Historical Comparison
GLO
BWAY

About GLO Clough Global Opportunities Fund

Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: